Compare iShares MSCI Taiwan ETF (EWT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Incyte Corporation — how do they compare? iShares MSCI Taiwan ETF trades at $106.55, while Incyte Corporation trades at $120.58 (market cap $24.54B). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| EWT | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $129.93 |
52-Week Low | $58.05 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $106.34, up 4.07% with strong bullish momentum. Technical indicators show moving averages strongly bullish while oscillators are neutral. The ETF benefits from Taiwan's AI-driven semiconductor exposure, with TSMC representing 22.5% weighting. Recent news highlights Taiwan's strong 2026 performance driven by AI chip demand, though some rotation from Asian AI winners has occurred.
Outlook remains positive given Taiwan's critical semiconductor role and AI infrastructure demand. Key risks include geopolitical tensions with China, foreign capital outflows, and semiconductor cycle volatility. The ETF's heavy tech concentration provides growth potential but increases sector-specific risk exposure.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
